Search
for
Sort by
Research 61–90 of 1000+
- ISID1394 - Long non-coding RNA AL136131.3 inhibits hair growth through mediating glycolysis in androgenetic alopecia
- ISID1417 - Interest of a cinchona succirubra extract and its association with caffeine in hair loss
- ISIDLB1680 - Effects of Ganoderma Lucidum extract and its active component, ganoderic acid A on hair loss prevention
- ESDR573 - Marine and Bovine-Derived Collagen Peptides Inhibit Catagen Development and Generate Diverse Effects on Stem Cells and Progeny in Human Scalp Hair Follicles Ex Vivo
- First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: A phase II study
- Integrated flow injection-solid phase spectrophotometric determination of minoxidil
- A Phase II Study of Vaginal Testosterone Cream (TEST) vs. Estring for Vaginal Dryness or Decreased Libido in Women with Early Stage Breast Cancer (BC) Treated with Aromatase Inhibitors (AIs).
- 519 Phase I/IIa clinical trial for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes
- 532P Analyses of patient-reported outcomes (PROs) with mirvetuximab soravtansine (MIRV) versus standard chemotherapy in the randomized phase III FORWARD I study in ovarian cancer (GOG 3011)
- INFLUENCE OF THE TYPE AND STYLE OF FEVER, SMOKING STATUS, DEGREE OF ANDROGENETIC ALOPECIA ON THE PHASES OF HAIR GROWTH IN MILITARY SERVICEMEN UNDER INPATIENT TREATMENT WITH A DIAGNOSIS OF PNEUMONIA
- Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
- 1428 DKK2 and SOSTDC1 cooperate to initiate the first catagen phase of the hair follicle growth cycle
- 586 Interest of Silybum marianum extract, Manganese PCA and Lespedeza capitata extract in a new anti-hair loss serum to stimulate hair growth and prolong anagen phase
- Two Phase 3 Trials of Baricitinib for Alopecia Areata
- Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors
- A Phase I Study of Topical Tempol for the Prevention of Alopecia Induced by Whole Brain Radiotherapy
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- STAT5 Activation in the Dermal Papilla Is Important for Hair Follicle Growth Phase Induction
- Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study
- The mouse hairy ears mutation exhibits an extended growth (anagen) phase in hair follicles and altered <i>Hoxc</i> gene expression in the ears
- Health-related quality of life with sacituzumab govitecan in HR+/HER2− metastatic breast cancer in the phase III TROPiCS-02 trial
- Small cell lung cancer: Results of a phase II study of 1,2,4 triglycidylurazol
- Two phase III trials of baricitinib for alopecia areata: a critically appraised research paper
- Development of Fast Reverse Phase Liquid Chromatographic Method for Simultaneous Analysis of Betamethasone Dipropionate and Calcipotriol in Ointments and Bulk Drug
- 62823 Optimization of deuruxolitinib dosing in adult patients with alopecia areata: Results from a randomized, parallel-group, multicenter, Phase 2 trial
- A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata
- LB785 Efficacy and safety of baricitinib in adults with Alopecia Areata: Phase 3 results from a randomized controlled trial (BRAVE-AA1)
- 41701 Efficacy of the Oral JAK1/JAK2 Inhibitor CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata: Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 Phase 3 Trial
- A Phase 1 Study to Investigate the Effects of Cortexolone 17α‐Propionate, Also Known as Clascoterone, on the QT Interval Using the Meal Effect to Demonstrate ECG Assay Sensitivity
- 26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study